

To: 5.1.2e | 5.1.2e | 5.1.2e | @rivm.nl]
From: 5.1.5 | @editorialmanager.com
Sent: Mon 3/15/2021 7:03:08 PM
Subject: Invitation to review a manuscript for BMC Medicine -BMED-D-21-00410 - [EMID:c24f18eb1f19c0d5]
Received: Mon 3/15/2021 7:03:08 PM

BMED-D-21-00410

Using syndromic measures of mortality to capture the dynamics of COVID-19 in Java, Indonesia in the context of vaccination roll-out
 Bimandra Adiputra Djaafara, MSc; 5.1.2e | 5.1.2e |, MSc; Oliver J Watson; Robert Verity; Nicholas F Brazeau; Widyastuti Widyastuti,
 MD; Dwi Oktavia, MD; Verry Adrian, MD; Ngabila Salama, MD; Sangeeta Bhatia; 5.1.2e | Nouvellet; Ellie Sherrard-Smith; 5.1.2e | 1.1
 Churcher; Henry Surendra; Rosa N Lina, MPH; Lenny L Ekawati, MPH; Karina D Lestari, BSc; Adhi Andrianto, BSc; Guy Thwaites; J
 Kevin Baird; Azra C Ghani; Iqbal RF Elyazar; Patrick GT Walker
 BMC Medicine

Dear 5.1.2e

I would like to invite you to review the manuscript above, which has been submitted to BMC Medicine. Further details including the full abstract can be found at the end of this email.

We operate a transparent peer review process for this journal where reviewer reports accompany publication of the article but the reviewer is not named (unless they opt in to include their name), which means that authors by default will not see the reviewers' names but only their comments. By agreeing to provide a report please understand that reviewer reports will be made available under an Open Access license Creative Commons CC-BY license (<http://creativecommons.org/licenses/by/4.0/>) if the manuscript is published.

If you wish, you can include your name in your published report. Please note you must decide whether to include your name at the start of the process and confirm this decision whenever prompted. If you change your decision later, we will not be able to publish your name.

If you are unable to review this paper, we would particularly appreciate suggestions for alternative reviewers from underrepresented communities. We aim for gender, race, ethnic, geographic, career stage and other diversity in our reviewer pool.

If you are able to review this submission please click on this link:

5.1.2h

If you are unable to review this submission please click on this link:

5.1.2h

We ask reviewers to return their report within 14 days of agreeing to review, however if you need more time please do let us know as we may be able to arrange an alternative deadline.

Reviewers are also expected to keep manuscripts confidential as outlined in our editorial policies:

5.1.2h

You are requested to submit your review online by using the Editorial Manager system which can be found at:

5.1.2h

If you have forgotten your username or password please use the "Send Login Details" link to get your login information. For security reasons, your password will be reset.

In order to keep delays to a minimum, please accept or decline this invitation online within the next few days. If you are unable to review the manuscript, we would be most grateful if you could suggest alternative reviewers.

If you review this manuscript you will be eligible for a 15% discount on one article processing charge for a manuscript submitted to one of the subject-specific journals in the BMC series 5.1.2h | or BMC Research Notes. This must be claimed on submission of the manuscript and is available for one year from completion of your review. Only one discount can be claimed on a submitted manuscript.

Thank you for your time, and I look forward to hearing from you.

Best wishes,

5.1.2e

BMC Medicine

<https://bmcmedicine.biomedcentral.com/>

BMED-D-21-00410

Research article

Using syndromic measures of mortality to capture the dynamics of COVID-19 in Java, Indonesia in the context of vaccination roll-out

Abstract: Background

As in many countries, quantifying COVID-19 spread in Indonesia remains challenging due to testing limitations. In Java, non-pharmaceutical interventions (NPIs) were implemented throughout 2020. However, as a vaccination campaign launches, cases and deaths are rising across the island.

Methods

We used modelling to explore the extent to which data on burials in Jakarta using strict COVID-19 protocols (C19P) provide additional insight into the transmissibility of the disease, epidemic trajectory, and the impact of NPIs. We assess how implementation of NPIs in early 2021 will shape the epidemic during the period of likely vaccine roll-out.

Results

C19P burial data in Jakarta suggest a death toll approximately 3.3 times higher than reported. Transmission estimates using these data suggest earlier, larger, and more sustained impact of NPIs. Measures to reduce sub-national spread, particularly during Ramadan, substantially mitigated spread to more vulnerable rural areas. Given current trajectory, daily cases and deaths are likely to increase in most regions as the vaccine is rolled-out. Transmission may peak in early 2021 in Jakarta if current levels of control are maintained. However, relaxation of control measures is likely to lead to a subsequent resurgence in the absence of an effective vaccination campaign.

Conclusions

Syndromic measures of mortality provide a more complete picture of COVID-19 severity upon which to base decision-making. The high potential impact of the vaccine in Java is attributable to reductions in transmission to date and dependent on these being maintained. Increases in control in the relatively short-term will likely yield large, synergistic increases in vaccine impact.

****Our flexible approach during the COVID-19 pandemic****

If you need more time at any stage of the peer-review process, please do let us know. While our systems will continue to remind you of the original timelines, we aim to be as flexible as possible during the current pandemic.

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at <https://www.springernature.com/production-privacy-policy>. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL [5.1.2h](#) Please contact the publication office if you have any questions.